Dutch hospital design conquers the world
The Netherlands is strong in the domain of healthcare architecture. In 2012, Dutch Health Architects together with Royal HaskoningDHV reached agreement with the client for the design of a 500 bed Cancer Center in China.
Dutch healthcare is known for its sustainable and innovative nature. The focus is on the creation of efficient, effective, accessible, comfortable and high-quality solutions that reduce costs, whilst increasing capacity and improving the quality of care and patient comfort.
The Netherlands were number one in the Euro Health Consumer Index 2012
Dutch Health Architects and Royal HaskoningDHV will design the new Cancer Center commissioned by the Honliv Group in Changyuan (Henan province), China. The Honliv Group wanted the design of the new Cancer Center to have the same quality as the hospitals they had visited in the Netherlands.
Royal HaskoningDHV also won, as part of a Danish-Dutch consortium, a design contract for an 150,000m² teaching hospital in Aalborg-Denmark. The focus of the design will be on the comfort of the patients, visitors and other users, creating a hospital environment that encourages an informal and personal atmosphere.
Galapagos partnering with Abbot: boost for development of novel rheumatoid arthritis product
The highly selective JAK1 inhibitor is currently in Phase II clinical development for rheumatoid arthritis, a disease that affects the joints, but which is also suspected of affecting the heart and lungs.
For Galapagos this is the biggest deal in their existence, as it could result in $1.35 billion including milestone payments. After a successful Phase II trial, Abbott will be responsible for the Phase III clinical development and global registration and manufacturing. Onno van de Stolpe CEO of Galapagos named Abbott (now called AbbVie), a global leader in autoimmune diseases, as “the best partner possible to deliver the complete clinical program and strong market introduction.”
The results of the Phase II trial are expected to be disclosed by the end of 2014. If successful, a drug could be on the market by the end of 2017. Galapagos’ pipeline covers four development programs and over 30 discovery programs in the areas of cancer, immuno-inflammatory diseases, osteoarthritis and rheumatoid arthritis.
Collaboration between Prosensa and GlaxoSmithKline continues to flourish
In 2012 Prosensa received £10 million in milestone payments from GlaxoSmithKline. The payment followed on from the successful selection of clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy.
The milestone payment exemplifies the continued fruitful collaboration between the two companies. Prosensa is contributing to the partnership the crucial technical know-how related to RNA-modulating therapeutics. GlaxoSmithKline brings to the table the expertise and experience required to promptly execute a late stage international multi-site clinical trial program in accordance with regulatory requirements.
Prosensa’s technology originally comes from Leiden University Medical Centre (LUMC). As explained by CEO Hans Schikan in a short documentary by the Dutch Ministry of Economic Affairs, the collaboration between Prosensa and LUMC, facilitated by funding from patient organizations such as Duchenne Parent Project NL and government organizations, is a great example of a public-private partnership which has led to the advancement of science, a potential treatment and the creation of new jobs.
Currently, the ultimate goal for all parties is the approval of drisapersen (GSK2402968/PRO051) as a treatment for Duchenne muscular dystrophy, a rare and severely debilitating childhood neuromuscular disease.